Acute and long-term neurological dysfunction including ischemic stroke remains an important complication of cardiovascular interventions. Lack of consistency in the neurological evaluation of patients involved in cardiovascular device trials and limited guidelines on trial protocols for neurological endpoints have made it challenging for clinicians and trialists to identify, evaluate, and report neurological complications following cardiovascular interventions. The Neurologic Academic Research Consortium (NeuroARC) classifies neurological events into 3 types based on clinical and neuroradiological examination; and categorizes cardiovascular interventions into safety and effectiveness trials based on the nature of the intervention and the associated neurological endpoints. Baseline and follow-up evaluation with valid neuropsychological tests and dedicated neuroimaging with diffusion-weighted magnetic resonance imaging are necessary to accurately characterize neurological events and their underlying mechanism of injury. Long-term follow-up is ideally required for a better understanding of differences in outcomes including long-term disability and morality, and cognitive impairment, especially in patients with subclinical neurological injury.
Stroke is one of the most devastating complications of any surgical or catheter-based cardiovascular intervention, and patients consider stroke a worse outcome than death.1
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com